Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico

Drug Abuse Clinical Trial

Official title:

SBIRT in New Mexico

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01131520
• Other study ID #: 08-08-173
• Secondary ID: R01DA026003
• Status: Completed
• Phase: N/A
• First received: May 21, 2010
• Last updated: November 15, 2017
• Start date: June 2010
• Est. completion date: July 2015

Study information

• Verified date: November 2017
• Source: Friends Research Institute, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness in reducing drug use and its associated problems of a brief intervention for drug use delivered by a behavioral health counselor as compared to a brief intervention delivered by a computerized intervention.

Description:

Drug use is a significant cause of morbidity and mortality in the United States. Efforts to develop and rigorously evaluate methods to provide Screening, Brief Intervention and Referral to Treatment (SBIRT) for drug users are needed. Computerized screening and brief interventions in particular have the potential to circumvent some of the potential problems of integrating SBIRT delivered by a counselor into busy primary care settings. These interventions may reduce drug use among individuals who are using drugs but are not yet drug dependent.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 360
• Est. completion date: July 2015
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older

• Moderate risk category on the ASSIST scores

Exclusion Criteria:

• planning to move out of New Mexico in the next year

• receipt of formal drug abuse treatment or a brief intervention for drug use in the past month.

Related Conditions & MeSH terms

• Drug Abuse
• HIV Risk Behavior
• Substance-Related Disorders

Intervention

Behavioral:
• Computerized brief intervention
This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
• Counselor delivered brief intervention
This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.

Locations

Country	Name	City	State
United States	Friends Research Institute	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Friends Research Institute, Inc.	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score	The ASSIST's Global Continuum of Illicit Drug Risk was used. A higher score is considered more severe risk. The scores range from 0 to 308.	3 months post-baseline
Primary	Hair Testing	The number of participants testing positive on Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and tetrahydrocannabinol (THC)	3 month post-baseline
Secondary	Human Immunodeficiency Virus (HIV) Drug Use Risk Assessment Battery Subscale	HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.	3 months post-baseline
Secondary	Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score	ASSIST's Global Continuum of Illicit Drug Risk Score which ranges from 0 to 308. A higher score is associated with higher risk.	6 month post-baseline
Secondary	Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score	ASSIST's Global Continuum of Illicit Drug Risk Score which ranges from 0 to 308. A higher score is associated with higher risk.	12 months post-baseline
Secondary	Hair Testing	The predicted probabilities for testing positive on Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and tetrahydrocannabinol (THC), calculated from generalized estimating equations.	6 month post-baseline
Secondary	Hair Testing	Predicted Probabilities for testing positive on the Radioimmunoassay (RIA) Hair Testing for opiates, cocaine, amphetamine and THC, calculated from generalized estimating equations.	12 month post-baseline
Secondary	Human Immunodeficiency Virus (HIV) Risk Assessment Battery Subscale	HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.	6 month post-baseline
Secondary	Human Immunodeficiency Virus (HIV) Risk Assessment Battery Subscale Score	HIV Drug Use Risk Assessment Battery Subscale Score ranges from 0 to 22. A higher score is considered to be associated with higher risk.	12 month post-baseline